

### TERM SHEET DETAILS

The signed term sheet between the Province of Manitoba and Providence Therapeutics also includes:

- **Future Economic Impact:** Providence will meet with Manitoba on a quarterly basis to review its expansion/growth plans, allowing Manitoba early awareness of possible economic development opportunities.
- **Priority of 2021 Supply:** Manitoba will receive the first 200,000 doses produced by Providence in 2021, with additional supply allocated on a pro-rata basis with other orders.
- **National Focus:** Manitoba will take on a leadership role in engaging other provincial and federal leaders of the importance of building Canadian-sourced capacity and security of mRNA vaccine supply.
- **Communications on Progress:** Manitoba will be able to track the progress of the order in real time including updates on the clinical trials and Health Canada's approval process.
- **Loss of Use:** If Manitoba does not require the doses upon delivery, a replacement buyer will be sought.